Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer

被引:1
作者
Garcia, Ainhoa [1 ,2 ]
Torres-Ruiz, Sandra [2 ]
Vila, Laura [2 ]
Villarroel-Vicente, Carlos [1 ,2 ]
Bernabeu, Alvaro [1 ]
Eroles, Pilar [2 ,3 ,4 ]
Cabedo, Nuria [1 ,2 ]
Cortes, Diego [1 ]
机构
[1] Univ Valencia, Dept Pharmacol, Valencia 46100, Spain
[2] Univ Clin Hosp Valencia, Inst Hlth Res INCLIVA, Valencia 46010, Spain
[3] Univ Valencia, Dept Physiol, Valencia 46010, Spain
[4] Ctr Biomed Network Res Canc CIBERONC, Madrid 28019, Spain
来源
RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 11期
关键词
DRUG DISCOVERY; APOPTOSIS; GENISTEIN; FAMILY; INHIBITORS; ESTROGEN; PATHWAY;
D O I
10.1039/d3md00385j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesis of three series of 2-aminopropyl derivatives containing a benzopyran nucleus was performed to evaluate their performance against triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-436) and normal breast epithelial cells (MCF10A). For the three series, the cytotoxic activity was as follows: N-methylated derivatives (tertiary amines) 5b, 6b, and 7b > secondary amine benzopyrans 5, 6, and 7 > quaternary amine salts 5c, 6c, and 7c > free phenolic derivatives 5a, 6a, and 7a. The structure-activity relationship showed the importance of the presence of an amine group and a p-fluorobenzyloxy substituent in the chromanol ring (IC50 values from 1.5 mu M to 58.4 mu M). In addition, 5a, 5b, 6a, and 7b displayed slight selectivity towards tumor cells. Compounds 5, 5a, 5b, 6, 6a, 6c, 7, and 7b showed apoptotic/necrotic effects due to, at least in part, an increase in reactive oxygen species generation, whereas 5b, 5c, 6b, 7a, and 7c caused cell cycle arrest in the G1 phase. Further cell-based mechanistic studies revealed that 5a, 6a, and 7b, which were the most promising compounds, downregulated the expression of Bcl-2, while 5b downregulated the expression of cyclins CCND1 and CCND2. Therefore, 2-aminopropyl benzopyran derivatives emerge as new hits and potential leads for developing useful agents against breast cancer.
引用
收藏
页码:2327 / 2341
页数:15
相关论文
共 50 条
  • [41] Resveratrol analogues surprisingly effective against triple-negative breast cancer, independent of ERα
    Horgan, Xylia J.
    Tatum, Hannah
    Brannan, Emily
    Paull, Daniel H.
    Rhodes, Lyndsay V.
    ONCOLOGY REPORTS, 2019, 41 (06) : 3517 - 3526
  • [42] Triple-Negative Breast Cancer Role of the Androgen Receptor
    Gucalp, Ayca
    Traina, Tiffany A.
    CANCER JOURNAL, 2010, 16 (01) : 62 - 65
  • [43] In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells
    Ozman, Zeynep
    Guney Eskiler, Gamze
    Sekeroglu, Mehmet R.
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (09)
  • [44] Alarming Burden of Triple-Negative Breast Cancer in India
    Thakur, Krishan K.
    Bordoloi, Devivasha
    Kunnumakkara, Ajaikumar B.
    CLINICAL BREAST CANCER, 2018, 18 (03) : E393 - E399
  • [45] MicroRNAs in regulation of triple-negative breast cancer progression
    Piasecka, Dominika
    Braun, Marcin
    Kordek, Radzislaw
    Sadej, Rafal
    Romanska, Hanna
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (08) : 1401 - 1411
  • [46] Targeting the androgen receptor in triple-negative breast cancer
    Gucalp, Ayca
    Traina, Tiffany A.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 141 - 150
  • [47] Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
    Agostinetto, Elisa
    Eiger, Daniel
    Punie, Kevin
    de Azambuja, Evandro
    CURRENT ONCOLOGY REPORTS, 2021, 23 (05)
  • [48] Green synthesis of ferrocenyl chalcones against triple negative breast cancer
    Tang, Wenqiang
    Gao, Yanrong
    Tong, Hongjuan
    Xu, Xiaona
    Zhu, Zhoujing
    Liu, Bin
    JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2023, 989
  • [49] Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer
    Luo, Ran
    Zhao, Haoyi
    Deng, Siqi
    Wu, Jiale
    Wang, Haijun
    Guo, Xiaoshan
    Han, Cuicui
    Ren, Wenkang
    Han, Yinglong
    Zhou, Jianwen
    Lin, Yu
    Bu, Ming
    MOLECULES, 2024, 29 (18):
  • [50] Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
    Kung, Che-Pei
    Cottrell, Kyle A.
    Ryu, Sua
    Bramel, Emily R.
    Kladney, Raleigh D.
    Bao, Emily A.
    Freeman, Eric C.
    Sabloak, Thwisha
    Maggi Jr., Leonard
    Weber, Jason D.
    ONCOGENE, 2021, 40 (01) : 189 - 202